Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 145   

Articles published

NVS 84.69 -1.48 (-1.72%)
price chart
Novartis Misses Revenues And Earnings Estimates
Novartis Misses Revenues And Earnings Estimates. Novartis AG (ADR) (NVS) reported results for the first quarter of its fiscal year 2014 (1QFY14) today, missing both revenues and earnings estimates.
Related articles »  
Buzz Stocks: Tesla Motors Inc (TSLA), Novartis AG (ADR), Allergan, Inc., and ...
Novartis AG (ADR) (NYSE:NVS) agreed to buy GlaxoSmithKline plc's (ADR) (NYSE:GSK) cancer drugs for up to $16 billion, and sell most of its vaccines division to GSK for $7.1 billion.
Bullish Stocks: Allergan (NYSE:AGN), Comcast Corporation (NASDAQ:CMCSA ...  Tech News
Hot Stocks: Allergan, Inc. (NYSE:AGN), Novartis AG (ADR) (NYSE:NVS), Netflix ...  Crazy Joys
Related articles »  
Novartis net profit jumps 24% to almost $3B
Novartis' (NVS) Q1 net profit leapt 24% to $2.97B and beat consensus of $2.7B, boosted by new drugs such as cancer treatment Afinitor and multiple sclerosis pill Gilenya.
Related articles »  
Novartis Trying to Simplify Business; Announces Deals With Glaxo And Eli Lilly
Novartis AG (ADR) (NVS) announced plans to overhaul its business today. The company plans to sell two units and buy another, in multiple transactions totaling $25 billion, which have the potential to increase to as much as $28.5 billion.
ADR Shares End Mixed; Novartis, Glaxo, Philips Shares Active  Wall Street Journal
GlaxoSmithKline plc (ADR) (NYSE:GSK) Divests Cancer Unit, Enters Joint ...  US Trade Media
Related articles »  
European Drug Names Traded Higher: AstraZeneca plc (NYSE:AZN), Novartis ...
The maker of Horlicks and Boost brands, GlaxoSmithkline plc (ADR) (NYSE:GSK) Consumer Healthcare, has kept its Indian consumer healthcare business out of its recently signed global JV agreement with Swiss major Novartis AG. On April 22, 2014.
Related articles »  
Almirall Quietly Building A Better Business
With that delay, Novartis (NVS) may well make it to market ahead of Forest/Almirall with the second LAMA+LABA combo. This isn't a trivial issue, as peak sales for the drug (single and combo) could top out between $1.75 billion and $2 billion against ...
What's Next For Biotech? [Novartis AG (ADR), Gilead Sciences, Inc., Amgen, Inc ...
whats-next Andy Crowder: I've been watching the biotech sector closely over the past few months. And like most investors, I'm wondering about the next move.
Novartis Gets Breakthrough Status For Oncology Drug
Novartis AG (ADR) (NVS) announced on March 26 that the US Food and Drug Administration (FDA) has granted its investigational compound, certinib (LDK378), a ´┐Żbreakthrough therapy´┐Ż status.
Related articles »  
Biotech Stocks With Exciting Development Projects
biotechnology Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar positively glows with important milestones that could ignite portfolios.
Related articles »  
Novartis' Lead Ceritinib Could Capture Market Share From Pfizer
Novartis A.G. and worldwide collaborators published results of their Phase I clinical trial of the ALK inhibitor Ceritinib (LDK378) in the New England Journal of Medicine on March 27.
Related articles »